SynthesisBMC musculoskeletal disorders2026
The efficacy and safety of adalimumab in treating axial spondyloarthritis: a systematic review and meta-analysis.
Synthesis in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAxial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disorder. Multiple randomized controlled trials (RCTs) have verified the efficacy of adalimumab for axSpA. Nevertheless, few integrated analyses explore its time-varying efficacy across different disease subtypes and age groups, and the optimal treatment time point and full respiratory disorders remain unclear.
methodsWe searched four electronic databases for eligible RCTs up to September 1, 2022. Two researchers independently screened literature and extracted data. Methodological bias was assessed using the Cochrane risk-of-bias tool, and Stata 15.0 was adopted for quantitative meta-analysis.
resultsNine studies involving 1113 patients were included. At week 12, adalimumab significantly increased ASAS20 [RR = 2.36, 95% CI (1.94, 2.87)], ASAS40 [RR = 3.16, 95% CI (2.46, 4.06)], ASAS5/6 [RR = 4.07, 95% CI (3.09, 5.37)] and ASAS partial remission [RR = 5.29, 95% CI (3.02, 9.26)] response rates. Disease activity indicators, including ASDAS [SMD = -1.31, 95% CI (-1.52, -1.09)] and BASDAI [SMD = -0.81, 95% CI (-0.99, -0.63)], were significantly lower, while CRP [SMD = -0.52, 95% CI (-0.70, -0.35)], total back pain [SMD = -0.68, 95% CI (-0.86, -0.49)], nighttime back pain [SMD = -0.69, 95% CI (-0.88, -0.50)], BASMI [SMD = -0.39, 95% CI (-0.58, -0.20)] and BASFI [SMD = -0.60, 95% CI (-0.77, -0.42)] were also markedly reduced. No significant between-group difference was detected in the incidence of adverse events. DISCUSSION: Adalimumab achieves peak efficacy at week 12, with comparable efficacy in radiographic and non-radiographic axSpA, and works effectively in adolescents aged ≥ 12 years. Despite possible infections, respiratory disorders and liver dysfunction, adalimumab possesses a favorable safety profile. These results underpin its standardized clinical use for axSpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.